{"id":"W4409546702","doi":"10.3389/fmed.2025.1548590","title":"A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial","year":2025,"lang":"en","type":"article","venue":"Frontiers in Medicine","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Custom Security Industries (Canada); University of Calgary; University of Toronto; Princess Margaret Cancer Centre; McMaster University; St. Paul's Hospital; University of British Columbia","funders":"Italfarmaco; Kiadis Pharma; Association of Community Cancer Centers; Incyte; CTI Biopharma; Genentech; Janssen Scientific Affairs; MEI Pharma; Arog Pharmaceuticals; Astex Pharmaceuticals; FibroGen; Gilead Sciences; Sanofi; MorphoSys; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Tolerability; Medicine; Discontinuation; Essential thrombocythemia; Internal medicine; Adverse effect; Polycythemia vera; Regimen; Clinical endpoint; Anagrelide; Dosing; Clinical trial; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002026953,0.001183378,0.001502658,0.0001913413,0.0007876134,0.0007799445,0.0008152899,0.0007989256,0.003057782],"category_scores_gemma":[0.0011345,0.000383642,0.0008588561,0.0006348705,0.0007031749,0.0005055744,0.0003936467,0.001279176,0.000483518],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004458894,"about_ca_system_score_gemma":0.007838489,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.1267419,"about_ca_topic_score_gemma":0.2188218,"domain_scores_codex":[0.999343,0.0002223347,0.00002582055,0.00009090723,0.0001343163,0.0001836133],"domain_scores_gemma":[0.9987158,0.00009671855,0.0002023035,0.00007867355,0.0001694035,0.0007371954],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7820113,0.01613843,0.1317554,0.0004407491,0.002817487,0.0004240571,0.0004172725,0.001299864,0.008563146,0.0005790367,0.01026837,0.04528486],"study_design_scores_gemma":[0.459135,0.09606066,0.4302128,0.00008162577,0.001950662,0.0005053306,0.000273965,0.002353961,0.001146755,0.0003165034,0.007858563,0.0001042084],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916222,0.00156218,0.0001428446,0.0005044565,0.00003840342,0.001550311,0.002475444,0.00003297263,0.002071335],"genre_scores_gemma":[0.9918617,0.0006952952,0.000632261,0.0006822444,0.0001037616,0.0008473253,0.00317409,0.00001030167,0.001992898],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8732581,"threshold_uncertainty_score":0.2520083,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01243194386384954,"score_gpt":0.2929638078176176,"score_spread":0.2805318639537681,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}